PARP1 and head and neck squamous cell carcinoma: Bortezomib was previously shown to activate apoptosis by modulating the expression of apoptotic proteins, activation of caspases, cleavage of PARP-1 protein and hypodiploidia and phosphatidylserine externalization in HNSCC cell lines46,48–52,56,57.